Concerned about a potential increased risk of heart-related conditions, a US Food and Drug Administration (FDA) committee has suggested limits to the use of testosterone replacement therapy (TRT).

Metabolic syndrome refers to a group of symptoms that may be related to obesity centered around the hormone-sensitive area of the belly.